Boundless Bio Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Boundless Bio, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021
Period EndingDec 2024Dec 2023Dec 2022Dec 2021
Revenue & Gross Profit
Revenue0.000.000.000.00
Cost of Revenue1.090.000.000.00
Gross Profit-1.090.000.000.00
Operating Expenses
Research & Development55.2742.6437.1619.28
Selling, General & Administrative18.0012.169.316.02
Operating Expenses72.1854.8046.4725.30
Operating Income-73.27-54.80-46.47-25.30
Other Income/Expense
Interest Income7.895.280.670.10
Interest Expense0.000.000.000.00
Other Income/Expense7.900.08-0.100.00
Income
Income Before Tax-65.36-49.43-45.90-25.21
Income Tax Expense0.000.000.000.00
Net Income-65.36-49.43-45.90-25.21
Net Income - Continuous Operations-65.36-49.43-45.90-25.21
Net Income - Discontinued Operations0.000.000.000.00
EBITDA-64.28-53.84-45.53-24.62
EBIT-65.36-54.80-46.47-25.30
Depreciation & Amortization1.090.960.940.68
Earnings Per Share
Basic EPS-4.00-2.00-42.00-29.00
Diluted EPS-4.00-2.00-42.00-29.00
Basic Shares Outstanding16.9822.241.100.86
Diluted Shares Outstanding16.9822.241.100.86